Meet us at CPHI Milan 2026, Booth No. 10H33, Oct 6-8, Fiera Milano, Italy Schedule a Meeting
Meet our scientific, technical, and commercial teams to explore how Neuland, a pure-play API CDMO, can support your molecule from development through commercial manufacturing.
40+ years of experience supporting small molecules, peptides, APIs, intermediates, and innovative development programs.
Explore our new Genome Valley R&D Centre featuring AI-driven route scouting, automation, advanced analytical capabilities, and integrated scale-up infrastructure.
Learn about our new 140,000 sq. ft. peptide CDMO facility designed for SPPS, LPPS, hybrid synthesis, purification, and commercial supply.
As a dedicated API manufacturer, discover how our three cGMP manufacturing facilities support development, technology transfer, commercial production, and lifecycle supply management.
✓ 40+ Years of Complex API Chemistry Expertise
✓ Pure-Play API Development & Manufacturing Partner
✓ AI-Enabled Process R&D Centre
✓ New Multi-Module Peptide Manufacturing Platform
✓ 3 cGMP Manufacturing Facilities
✓ Global Regulatory Track Record
✓ Agile & Transparent Partnerships
Whether you're advancing a new molecule, scaling a peptide program, securing commercial supply, or evaluating future manufacturing partners, we'd welcome the opportunity to discuss your goals.
Event Name – CPHI Milan
Booth No #10H33
6th Oct to 8th Oct
Neuland Laboratories operates manufacturing facilities that are regularly inspected by leading global regulatory authorities. With over four decades of experience supporting pharmaceutical and biotechnology companies, Neuland maintains robust quality systems and cGMP-compliant operations to support development and commercial manufacturing programs worldwide.
Neuland Laboratories provides end-to-end CDMO services across the development lifecycle, including process chemistry, analytical development, API development and manufacturing, custom synthesis, regulatory support, and commercial-scale production. The company supports both small molecules and peptides for innovator pharmaceutical and biotech companies.
Neuland's purpose-built peptide manufacturing facility spans 140,000 sq. ft. and features 7 kL of combined SPPS and LPPS reactor capacity. The facility also includes 300 L of integrated lyophilization capacity and 45 cm and 60 cm DAC purification systems, enabling efficient peptide development, scale-up, and GMP manufacturing from clinical to commercial stages.
Neuland's manufacturing and R&D facilities are located in Hyderabad, India. Its integrated network of development, manufacturing, and quality operations enables seamless scale-up from early-stage development through commercial production while serving customers across global markets.
Neuland supports a broad range of complex pharmaceutical programs, including small-molecule APIs, advanced intermediates, and therapeutic peptides. The company specializes in solving complex chemistry and manufacturing challenges throughout the drug development lifecycle.
CPHI Milan 2026 provides an opportunity to meet Neuland's scientific, technical, and business development teams to discuss API development, peptide manufacturing, commercial scale-up, supply chain strategies, and long-term CDMO partnerships tailored to your program requirements.
You can request a meeting with Neuland before or during CPHI Milan 2026 through the event contact form. Our team will coordinate a suitable time to discuss your development, scale-up, or commercial manufacturing needs.
Yes. Neuland offers integrated development and manufacturing services that support programs from early-stage process development and analytical characterization through clinical supply, regulatory support, and commercial manufacturing.
Neuland combines over 40 years of manufacturing experience, regulatory expertise, complex chemistry capabilities, and a customer-focused approach to help pharmaceutical and biotech companies accelerate development while maintaining quality and supply reliability.
